Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.
Publication
, Journal Article
Hoppe, RT; Advani, RH; Ai, WZ; Ambinder, RF; Aoun, P; Bello, CM; Benitez, CM; Bernat, K; Bierman, PJ; Blum, KA; Chen, R; Dabaja, B; Forero, A ...
Published in: J Natl Compr Canc Netw
May 2017
This portion of the NCCN Guidelines for Hodgkin lymphoma (HL) focuses on the management of classical HL. Current management of classical HL involves initial treatment with chemotherapy or combined modality therapy followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale). The introduction of less toxic and more effective regimens has significantly advanced HL cure rates. However, long-term follow-up after completion of treatment is essential to determine potential long-term effects.
Duke Scholars
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
May 2017
Volume
15
Issue
5
Start / End Page
608 / 638
Location
United States
Related Subject Headings
- United States
- Prognosis
- Oncology & Carcinogenesis
- Neoplasm Staging
- Medical Oncology
- Humans
- Hodgkin Disease
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Hoppe, R. T., Advani, R. H., Ai, W. Z., Ambinder, R. F., Aoun, P., Bello, C. M., … Sundar, H. (2017). Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(5), 608–638. https://doi.org/10.6004/jnccn.2017.0064
Hoppe, Richard T., Ranjana H. Advani, Weiyun Z. Ai, Richard F. Ambinder, Patricia Aoun, Celeste M. Bello, Cecil M. Benitez, et al. “Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw 15, no. 5 (May 2017): 608–38. https://doi.org/10.6004/jnccn.2017.0064.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, et al. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 May;15(5):608–38.
Hoppe, Richard T., et al. “Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology.” J Natl Compr Canc Netw, vol. 15, no. 5, May 2017, pp. 608–38. Pubmed, doi:10.6004/jnccn.2017.0064.
Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Benitez CM, Bernat K, Bierman PJ, Blum KA, Chen R, Dabaja B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Huang J, Johnston PB, Kaminski MS, Kenkre VP, Khan N, Maloney DG, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Mulroney C, Poppe M, Rabinovitch R, Seropian S, Smith M, Winter JN, Yahalom J, Burns J, Ogba N, Sundar H. Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 May;15(5):608–638.
Published In
J Natl Compr Canc Netw
DOI
EISSN
1540-1413
Publication Date
May 2017
Volume
15
Issue
5
Start / End Page
608 / 638
Location
United States
Related Subject Headings
- United States
- Prognosis
- Oncology & Carcinogenesis
- Neoplasm Staging
- Medical Oncology
- Humans
- Hodgkin Disease
- 4203 Health services and systems
- 3211 Oncology and carcinogenesis